白蛋白结合型紫杉醇联合顺铂同步放疗治疗晚期子宫颈癌的临床效果  

Clinical Effect of Albumin-bound Paclitaxel Combined with Cisplatin Concurrent Radiotherapy in the Treatment of Advanced Cervical Cancer

作　　者：林佳[1] 王丹丹 林庆纯 陈斌[1] 庄梅生[1] LIN Jia;WANG Dandan;LIN Qingchun;CHEN Bin;ZHUANG Meisheng(Jieyang People's Hospital,Guangdong Province,Jieyang 522000,China)

机构地区：[1]广东省揭阳市人民医院,广东揭阳522000

出　　处：《中国医学创新》2023年第35期10-14,共5页Medical Innovation of China

基　　金：揭阳市科技局计划项目(YLWS068)。

摘　　要：目的:探讨白蛋白结合型紫杉醇联合顺铂同步放疗治疗晚期子宫颈癌的临床效果。方法:选择揭阳市人民医院2020年9月—2022年9月收治的100例晚期子宫颈癌患者作为研究对象,用随机数字表法将患者分为对照组和观察组,每组50例。对照组用溶剂型紫杉醇和顺铂加同步放疗治疗,观察组用白蛋白结合型紫杉醇和顺铂加同步放疗治疗。比较两组治疗效果、毒副反应、肿瘤标志物水平和生活质量评分。结果:观察组的缓解率和控制率均比对照组高,差异均有统计学意义(P<0.05)。观察组的腹泻发生率比对照组低,差异有统计学意义(P<0.05)。治疗后,观察组的糖类抗原125(CA125)和鳞状上皮细胞癌相关抗原(SCC-ag)水平均比对照组低,差异均有统计学意义(P<0.05)。治疗后,观察组的生活质量各维度评分均比对照组高,差异均有统计学意义(P<0.05)。结论:白蛋白结合型紫杉醇和顺铂同步放化疗治疗晚期子宫颈癌比溶剂型紫杉醇更有效,能够进一步降低患者肿瘤标志物水平,减少腹泻的发生率,同时提高患者生活质量。Objective:To explore the clinical effect of albumin-bound Paclitaxel combined with Cisplatin concurrent radiotherapy in the treatment of advanced cervical cancer.Method:A total of 100 patients with advanced cervical cancer admitted to Jieyang People's Hospital from September 2020 to September 2022 were selected as the research objects,patients were divided into the control group and the observation group by random number table method,50 cases in each group.The control group was treated with solvent-based Paclitaxel and Cisplatin plus concurrent radiotherapy,and the observation group was treated with albumin-bound Paclitaxel and Cisplatin plus concurrent radiotherapy.The therapeutic effect,toxicity,tumor marker level and quality of life score were compared between the two groups.Result:The objective remission rate and disease control rate of the observation group were higher than those of the control group,the differences were statistically significant(P<0.05).The incidence of diarrhea in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).After treatment,the levels of carbohydrate antigen 125(CA125)and squamous cell carcinomaassociated antigen(SCC-ag)in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the quality of life scores of each dimension in the observation group were higher than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Albumin-bound Paclitaxel and Cisplatin concurrent chemoradiotherapy are more effective than solvent-based Paclitaxel in the treatment of advanced cervical cancer,which can further reduce the levels of tumor markers in patients,reduce the incidence of diarrhea,and improve the quality of life of patients.

关 键 词：白蛋白结合型紫杉醇 顺铂 放疗 晚期子宫颈癌 

分 类 号：R737.33[医药卫生—肿瘤]